Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Metastasis02:30

Metastasis

6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Detection of Ultrahigh Energy Emission from Gamma-Ray Binary LS I +61° 303.

Physical review letters·2026
Same author

Evidence of Cosmic-Ray Acceleration up to Sub-PeV Energies in the Supernova Remnant IC 443.

Physical review letters·2026
Same author

Precise Measurement of the Cosmic Ray Helium Spectrum above 0.1 PeV.

Physical review letters·2026
Same author

Correction: Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

Oncogene·2026
Same author

All-Sky Search for Individual Primordial Black Hole Bursts with LHAASO.

Physical review letters·2025
Same author

Measurement of Very-High-Energy Diffuse Gamma-Ray Emissions from the Galactic Plane with LHAASO-WCDA.

Physical review letters·2025

Related Experiment Video

Updated: Feb 24, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Donor-Derived Metastatic Melanoma and Checkpoint Inhibition.

S M Boyle1, N Ali2, A J Olszanski2

  • 1Division of Nephrology, Drexel University College of Medicine, Philadelphia, Pennsylvania.

Transplantation Proceedings
|August 26, 2017
PubMed
Summary
This summary is machine-generated.

Donor-derived melanoma is a rare complication of kidney transplants. This case shows successful treatment with immunosuppression withdrawal, allograft removal, and targeted melanoma therapies.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
07:31

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

18.3K

Related Experiment Videos

Last Updated: Feb 24, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
07:31

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

18.3K

Area of Science:

  • Oncology
  • Transplantation Immunology
  • Nephrology

Background:

  • Donor-derived malignancy is a rare but serious complication following organ transplantation.
  • Metastatic melanoma poses a significant challenge in transplant recipients due to immunosuppression.

Observation:

  • A case of metastatic melanoma was diagnosed in a deceased-donor kidney transplant recipient.
  • The patient presented with a rare complication of donor-derived malignancy.

Findings:

  • Successful treatment involved cessation of immunosuppression, explantation of the renal allograft, and novel melanoma therapies.
  • The patient received targeted agents (dabrafenib, trametinib) and an immune checkpoint inhibitor (nivolumab).

Implications:

  • This case highlights the potential efficacy of modern melanoma therapies in managing donor-derived malignancies.
  • The successful outcome demonstrates a shift from near-certain mortality to potential cure for metastatic melanoma in this context.
  • Experience with targeted agents and immune checkpoint inhibitors in dialysis-dependent patients with donor-derived melanoma is reported.